|
|
||||||||
1 Filovirus Laboratory, Claude Bernard University Lyon 1, INSERM U758, IFR 128 BioSciences Lyon-Gerland, 21 avenue Tony Garnier, 69365 Lyon Cedex 07, France
2 School of Molecular and Microbial Sciences, University of Queensland, St Lucia, Brisbane, Queensland 4072, Australia
Correspondence
Viktor E. Volchkov
volchkov{at}cervi-lyon.inserm.fr
| ABSTRACT |
|---|
|
|
|---|
1 and
5 integrins and major histocompatibility complex I molecules. The level of GP expression in Kunjin replicon GP-expressing cells was similar to that observed in cells infected with EBOV early in infection and lower than that produced in cells transfected with plasmid DNA, phCMV-GP, expressing GP from a strong promoter. Importantly, transient transfection of Kunjin replicon GP-expressing cells with GP-coding plasmid DNA resulted in overexpression of GP, which lead to the downregulation of surface molecules and massive rounding and detachment of transfected cells. Here, it was also demonstrated that cell rounding and downregulation of the surface markers are the late events in EBOV infection, whereas synthesis and massive release of virus particles occur at early steps and do not cause significant cytotoxic effects. These findings indicate that the synthesis of EBOV GP in virus-infected cells is controlled well by several mechanisms that do not allow GP overexpression and hence the early appearance of its cytotoxic properties. | INTRODUCTION |
|---|
|
|
|---|
Unlike the GP of the closely related MARV, that of EBOV is encoded by two overlapping reading frames. Expression of EBOV GP requires insertion of a non-templated adenosine residue at the so-called editing site during GP mRNA synthesis (Sanchez et al., 1996
; Volchkov et al., 1995
). During virus replication, expression of surface GP is therefore limited since most GP gene-specific mRNAs (80 %) direct synthesis of the secreted non-structural glycoprotein, sGP (Sanchez et al., 1998
; Volchkova et al., 1998
).
Expression of EBOV GP from recombinant adenoviruses or transfected plasmids causes massive rounding and cell detachment in several cell lines including human umbilical vein endothelial cells (HUVEC). These so-called cytotoxic properties of EBOV GP are believed to contribute to the disruption of blood vessel integrity and thus play a major role in the haemorrhagic symptoms developed during the disease (Ray et al., 2004
; Yang et al., 2000
). Morphological changes observed upon transient expression of GP in cells correlate with downregulation of surface expression of several proteins including certain integrins and immune molecules (Chan et al., 2000b
; Simmons et al., 2002
; Takada et al., 2000
; Yang et al., 2000
). Recently, Sullivan et al. (2005)
demonstrated that GP exerts its toxic effects by altering the transport of a specific subset of cellular proteins, depending on the cell type, through a process dependent on dynamin, a cellular GTPase involved in protein trafficking. The importance of GP cytotoxicity in viral pathogenesis is however controversial, since direct damage to the microvascular endothelia by virus replication is very limited and only documented in animal models at terminal stages of the disease (Geisbert et al., 2003c
; Ryabchikova et al., 1999
).
In this study, we demonstrate that massive release of virus particles from EBOV-infected 293T cells precedes the appearance of cytotoxic effects and/or downregulation of cell surface markers. Moreover, using the Kunjin flavivirus self-replicon system (Khromykh & Westaway, 1997
), we show that a continuous and moderate expression of EBOV GP does not cause cell rounding or detachment. Cytotoxic effects of GP were however observed in the Kunjin replicon GP-expressing cells when the GP protein was overexpressed from a transiently transfected plasmid DNA encoding the GP gene under the control of a strong promoter, CMV (cytomegalovirus). Taken together, our results suggest that moderate levels of GP expression, as seen in the Kunjin replicon system or at early steps of EBOV infection, may have a limited impact on the functioning of cells.
| METHODS |
|---|
|
|
|---|
Recombinant EBOV subtype Zaire strain Mayinga (recEBOe+) has been described previously (Volchkov et al., 2001
). Stock virus was propagated in Vero E6 cells and stored at 80 °C. For virus titration, Vero E6 cells were inoculated with different dilutions of culture medium containing EBOV and incubated for 1 h at 37 °C. Fresh medium containing 5 % FCS was then added; cells were cultivated for 79 days and subsequently fixed and stained with 10 % formaldehyde containing 0·1 % crystal violet. Cytopathic effect was evaluated under a light microscope and the TCID50 was calculated using Karber's formula. 293T cells were infected at an m.o.i. of 4. After incubation with virus for 1 h at 37 °C, fresh medium containing 10 % FCS was added to get 5 % FCS final concentration. Aliquots of medium were collected at different intervals up to 8 days post-infection. Proteins from cells and culture supernatant were collected and analysed separately. Mock-infected cells were used as a negative control.
Recombinant plasmids.
The GP gene of Zaire EBOV was extracted from pGEM-mGP8A (Volchkov et al., 1995
) using BamHI and HindIII endonucleases and cloned into the phCMV plasmid linearized with BamHI, a vector designed to express high amounts of the protein of interest (Yee et al., 1994
). The restriction sites in the vector and insert were filled-in with Klenow enzyme before ligation. The resulting plasmid was designated phCMV-GP. The GP gene was also cloned into the pIRES2-eGFP plasmid (Clontech), a vector designed for simultaneous expression of the protein of interest and enhanced green fluorescent protein (eGFP). In this case, the GP gene was extracted from phCMV-GP using EcoRI endonuclease and introduced into the unique EcoRI restriction site of the plasmid vector. The resulting plasmid was designated pIRES2-eGFP-GP.
To generate pKUNrep4-GP, the GP gene was amplified by PCR using primers supplemented with MluI restriction site (underlined): GP-MluI-F 5'-AAAACGCGTTGCAGTTACCTCGTGATCGATTC-3' and GP-MluI-R 5'-TTTACGCGTCTAAAAGACAAATTTGCATATACAG-3'. The resulting PCR fragment was cloned into the unique MluI restriction site of the pKUNrep4 vector (Varnavski et al., 2000
). Sequences of all recombinant plasmids were confirmed by sequence analysis.
Establishment of cell lines expressing Kunjin virus replicons.
293T cells were transfected with pKUNrep4 or pKUNrep4-GP using Exgen 500 transfection reagent (Euromedex) following the manufacturer's instructions. Briefly, cells grown in 21 cm2 Petri dishes (
50 % confluence) were transfected with 2 µg plasmid. After 6 h of incubation, the transfection mixture was removed and replaced by culture medium containing 5 % FCS. At 24 h post-transfection, puromycin (1 µg ml1) was added to the culture medium. After 5 days of cultivation, clones of cells were isolated and screened by Western blot for the expression of Kunjin NS5 protein alone or Kunjin NS5 plus EBOV GP. Clones expressing Kunrep4 and Kunrep4-GP replicons were designated Kun and KunGP, respectively, and were then cultured in the presence of puromycin (1 µg ml1). Kun14 and KunGP12 cell clones were assayed after 510 passages and in total were passaged more than 30 times.
Immunoblotting analysis.
293T cells were lysed in 350 µl (50 µl per cm2 of cells) of 1x Laemmli sample buffer [2 % SDS, 5 % 2-mercaptoethanol, 13 % (w/v) glycerol and 0·2 % bromophenol blue] and heated for 15 min at 95 °C. Cell lysates were subjected to digestion with EndoH or PNGase F performed following the manufacturer's instructions (New England Biolabs) or used untreated. Proteins were separated on 10 % SDS-PAGE and blotted onto PVDF membrane (Millipore). Primary antidodies used were horse anti-EBOV (1 : 5000), rabbit anti-GP2 of EBOV (1 : 2000), rabbit anti-VP24 of EBOV (1 : 4000), mouse anti-NS5 of Kunjin virus (1 : 50) and rabbit anti-actin antibodies (1 : 100; Sigma). Horseradish peroxidase-conjugated secondary antibodies used were rabbit anti-horse (1 : 50 000; Sigma) and goat anti-rabbit antibodies (1 : 20 000; Dako) and anti-mouse antibodies (1 : 20 000; Dako). Proteins were visualized using SuperSignal West Dura Extended Duration substrate following the manufacturer's instructions (Perbio Science).
RT-PCR.
Total RNA was extracted from KunGP12 and KunGP8 cell clones using RNeasy Mini kit (Qiagen). cDNA of the GP gene was generated using the following oligonucleotides: pKUN-F 5'-CAACCTCCCCTTCTACGAGCGGCTC-3' and pKUN-R 5'-CAAACGCACACCGGCCTTATTCCAAG-3', and OneStep RT-PCR kit (Qiagen). PCR products were separated by electrophoresis on a 1 % agarose gel, the GP-specific band was extracted from the gel using QIAquick Gel Extraction kit (Qiagen) and then used for sequencing.
Pulsechase labelling and immunoprecipitation.
Pulsechase analysis was performed as described previously (Volchkov et al., 1998
) on KunGP12 cells grown until confluent (approx. 72 h), on 293T cells 16 h post-transfection with phCMV-GP vector as a positive control and with a GFP-expressing plasmid as a negative mock-control. Briefly, cells were starved for 1 h with methionine- and cysteine-free DMEM medium, and were then labelled with 100 µCi (3·7 MBq) ml1 [35S]Promix (CysMet) (Amersham Biosciences) for 45 min in the case of the KunGP12 cells or 30 min in the case of transient transfection. After the pulse-labelling, cells were chased for different time intervals. Finally, labelled cells were lysed at 4 °C in Co-IP buffer (1 % Nonidet P-40, 0·4 % sodium deoxycholate, 0·5 % BSA, 5 mM EDTA, 100 mM NaCl, 20 mM Tris/HCl, pH 7·6, 25 mM iodacetamide, 1 mM PMSF). Immunoprecipitation was performed using horse anti-EBOV and rabbit anti-horse antibodies (Sigma) coupled to protein ASepharose (Sigma). Samples were separated on 10 % SDS-PAGE and analysed by autoradiography.
Immunofluorescence analysis.
Cells grown on glass coverslides were washed twice with PBS, fixed for 5 min with 3 % paraformaldehyde at room temperature, rinsed twice with PBS, incubated with 0·1 M glycine for 10 min at room temperature and then washed with PBS. To avoid non-specific binding, slides were first incubated with blocking buffer [PBS, 2 % BSA, 5 % (w/v) glycerol, 0·2 % Tween 20] for 5 min and then with anti-GP KZ52 antibodies diluted 1 : 250 in blocking buffer for 1 h incubation at room temperature. For intracellular labelling of Kunjin NS5 cytoplasmic protein, cells were permeabilized using PBS containing 0·2 % Triton X-100 for 5 min at room temperature, washed twice and incubated for 1 h with Kunjin anti-NS5 rabbit antibodies. The slides were then treated for 1 h with a mixture of secondary antibodies: fluorescein isothiocyanate (FITC)-coupled rabbit anti-human antibodies (1 : 200) and tetramethylrhodamine isothiocyanate (TRITC)-coupled rabbit anti-mouse antibodies (1 : 300; Dako). Finally, the coverslides were washed and mounted with fluorescent mounting medium (Dako). Microscopic analysis was performed using an Axiovert 200M fluorescence microscope (Zeiss).
Flow cytometry.
293T cells were transfected with phCMV or phCMV-GP and analysed after 24 h of growth. EBOV-infected cells or the mock control were analysed 24 and 48 h post-infection. Kun14 and KunGP12 cells were grown until confluent prior to flow cytometry analysis. Cells were collected, pooled with floating cells and were washed in cold PBS supplemented with 2 % FCS (PBS/FCS). Cells were incubated for 1 h with primary antibodies, washed three times with PBS/FCS and then incubated for 30 min with secondary antibodies.
1 integrin and MHC I molecules were detected using phycoerythrin (PE)-coupled antibodies CD29 (1 : 10; Becton Dickinson) and HLA-ABC (1 : 12·5; BD Biosciences).
5 integrin was labelled using biotin-conjugated mouse anti-CD49 (1 : 5; BD Biosciences) and followed by incubation with PE-coupled streptavidin (Catlag). EBOV GP was detected by using anti-GP human KZ52 antibodies (1 : 150) followed by incubation with swine anti-human FITC-coupled antibodies (1 : 50; Dako). Cells were analysed using Becton Dickinson or Beckmann Coulter flow cytometers and CellQuestPro software (BD Biosciences).
| RESULTS |
|---|
|
|
|---|
|
1 and
5 integrins but also MHC I proteins in 293T cells (Simmons et al., 2002
1 and
5 integrins and MHC I molecules by flow cytometry. At 24 h post-infection the levels of cell surface markers were not yet affected, whereas over 50 % of cells were clearly positive for the surface expression of GP (Fig. 1c
Expression of EBOV GP from Kunjin virus replicons
We felt that there was a large difference in the kinetics of protein expression between EBOV infection and cells transfected with the GP-expressing plasmids. In the transient expression system, the synthesis of GP occurs rapidly and reaches its highest level soon after transfection. In contrast, in EBOV-infected cells, synthesis of this protein occurs gradually and the level of expression depends on the virus replication rate. We therefore generated an expression system where the level of protein synthesis could be regulated, but more importantly, was dependent on cell viability. The flavivirus Kunjin (KUN) replicon-based system was previously used to develop stable cell lines continuously expressing different heterologous genes (Khromykh & Westaway, 1997
; Varnavski et al., 2000
). In this system, KUN replicon RNA is initially synthesized from transfected plasmid DNA containing the replicon coding sequence placed under the control of a CMV promoter (Fig. 2a
). Subsequent synthesis of the replicon RNA molecules is directed by the Kunjin non-structural (NS) proteins encoded by the replicon RNA. In the KUN replicon vector pKUNrep4 (Varnavski et al., 2000
), genes encoding structural proteins of the Kunjin virus are deleted and replaced by a sequence encoding a polyprotein consisting of fused puromycin acetyl transferase (PAC), Foot-and-mouth disease virus (FMDV)-2A autoprotease and the gene encoding the protein of interest (Fig. 2a
). Kunjin virus NS proteins required for replication of the replicon RNA are synthesized independently from the encephalomyelocarditis virus internal ribosome entry site (IRES). To express EBOV GP from this system, cDNA coding this protein was cloned into the unique MluI cloning site of the pKUNrep4 vector (Varnavski et al., 2000
). GP with the authentic amino acid sequence is generated following proteolytic processing of the fused polyprotein by the FMDV-2A autoprotease. The synthesis of GP with an authentic C terminus is ensured by incorporating the translation termination codon at the end of the GP sequence. Importantly, synthesis of PAC encoded by the KUNrep4 replicon (Fig. 2a
) allows establishment of cell lines continuously expressing EBOV GP by selection with puromycin.
|
|
The absence of cytotoxic effects in KunGP12 cells could also be due to defects in GP processing and transport. We therefore first examined the processing of GP in KunGP12 cells by pulsechase labelling followed by immunoprecipitation analysis using anti-EBOV antibodies. As shown in Fig. 4
(a), the processing of GP in KunGP12 and in phCMV-GP transfected cells was not different. GP was first identified as an endoplasmic precursor GPer that was later transported into the Golgi and then cleaved into GP1 and GP2 subunits (Volchkov et al., 1998
). Earlier detection of the GP1 and GP2 subunits in KunGP12 cells can be explained by the longer pulse labelling necessary to enhance the sensitivity of the method. The identity of the GPer and mature GP1 bands in KunGP12 cell extracts was confirmed by EndoH treatment (Fig. 4b
). As expected GPer contained high mannose sugars as indicated by its sensitivity to EndoH treatment, whereas mature GP1 contained complex sugars and was therefore EndoH resistant. Since the kinetics of GP synthesis were similar, we also compared the accumulation of different processing intermediates in both systems using Western blot analysis of cell lysates. Interestingly, the majority of intracellular GP in KunGP12 cells consisted of mature GP1GP2 complexes, whereas a clear accumulation of GPer was found in phCMV-GP transfected cells (Fig. 4b
, right panel).
|
|
5 and
1 integrins and MHC I proteins as early as 2024 h post-transfection (Fig. 6a
|
1 integrin and GFP expression. As shown in Fig. 6(b)
1-integrin in both Kun14 and KunGP12 cells, confirming that Kun replicons do not interfere with GP-induced cytotoxicity. Moreover, these results demonstrate that the level of GP expression is a critical factor for GP-induced cytotoxicity as increasing the amount of GP synthesized in the cells caused cytotoxic effects visualized by both cell rounding and detachment and also dowregulation of surface markers. | DISCUSSION |
|---|
|
|
|---|
Cytotoxic effects that appear later in EBOV infection could be explained by several other factors in addition to GP overexpresssion. Indeed, electron microscopy data indicates that infected cells are overloaded with assembled viral nucleocapsids (Geisbert & Jahrling, 1995
; Zaki & Goldsmith, 1999
). Moreover, other viral proteins can be toxic. For example, VP40, a major structural protein of EBOV has been shown to interact with cellular tubulin and to induce budding of virus-like particles (Jasenosky et al., 2001
; Ruthel et al., 2005
; Timmins et al., 2001
) but also caused intensive cell rounding when overexpressed (unpublished observations).
EBOV and the closely related MARV have very similar pathogenesis (Mahanty & Bray, 2004
). Surprisingly, it has been reported that the GP of MARV is not cytotoxic when transiently expressed from transfected plasmid DNA (Chan et al., 2000a
; Will et al., 1993
). However, when we expressed MARV GP from the phCMV vector, a cytotoxicity similar to that caused by EBOV GP was also observed, although it occurred later in transfection (48 h) and required higher amounts of plasmid DNA (unpublished data). Interestingly, these two viruses differ with respect to their GP expression strategy. The GP gene of MARV encodes only GP synthesized from a single open reading frame (Will et al., 1993
). The difference in the organization of the GP genes suggests that more GP should be expressed in cells infected with MARV than in EBOV-infected cells. In this respect, the lower cytotoxicity of MARV GP (in comparison with the GP of EBOV) means that the requirement to control GP-induced cytotoxicity was evolutionarily linked only to EBOV and resulted in very special strategy for GP expression (transcriptional RNA-editing). However, when overexpressed the surface glycoproteins of both filoviruses are similar in inducing strong cytotoxic effects.
Cytotoxicity caused by EBOV GP expression is believed to play an important role in the haemorrhagic manifestations widely observed in patients and laboratory-infected monkeys (Simmons et al., 2002
; Sullivan et al., 2005
; Yang et al., 2000
). However, direct damage of endothelial cells by virus replication is unlikely to be the first determinant of vascular injury. Involvement of the endothelial cells in virus replication was not confirmed in several detailed analyses of virus infection in monkeys (Geisbert & Jahrling, 2003
; Geisbert et al., 2003a
, b
, c
; Ryabchikova et al., 1999
). It appears that damage to the endothelial barrier leading to loss of vascular integrity and haemorrhage syndrome, more likely results from the effect of the aberrant cytokine profiles of cells of the mononuclear phagocytic system, which are the primary target cells of the virus (Bray & Geisbert, 2005
; Geisbert & Jahrling, 2003
; Gibb et al., 2002
; Gupta et al., 2001
; Ryabchikova et al., 1999
). Here, downregulation of the cell surface markers, a phenomenon observed in virus-infected cells at later stages of infection could be very important. It has been reported that infection of these cells leads to their incomplete activation and triggers an inappropriate immune response contributing to the high pathogenicity of the disease (Bray & Geisbert, 2005
; Gibb et al., 2002
; Gupta et al., 2001
; Stroher et al., 2001
). The immune response is known to be subtly regulated by cell-to-cell contacts and interactions between cell surface proteins. Thus, the effects caused by GP expression even at a moderate level could contribute to the inhibition of the host's ability to mount an effective immune defence. Molecular mechanisms that allow cells, particularly dendritic cells, to escape the cytotoxic effects caused by virus replication and GP expression for an extended period have not as yet been determined. Understanding these mechanisms will make an important contribution in the fight against filovirus infections.
| ACKNOWLEDGEMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
Chan, S. Y., Ma, M. C. & Goldsmith, M. A. (2000a). Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol 81, 21552159.
Chan, S. Y., Speck, R. F., Ma, M. C. & Goldsmith, M. A. (2000b). Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol 74, 49334937.
Dolnik, O., Volchkova, V., Garten, W., Carbonnelle, C., Becker, S., Kahnt, J., Stroher, U., Klenk, H. D. & Volchkov, V. (2004). Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 23, 21752184.[CrossRef][Medline]
Geisbert, T. W. & Jahrling, P. B. (1995). Differentiation of filoviruses by electron microscopy. Virus Res 39, 129150.[CrossRef][Medline]
Geisbert, T. W. & Jahrling, P. B. (2003). Towards a vaccine against Ebola virus. Expert Rev Vaccines 2, 777789.[CrossRef][Medline]
Geisbert, T. W., Hensley, L. E., Jahrling, P. B. & 7 other authors (2003a). Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362, 19531958.[CrossRef][Medline]
Geisbert, T. W., Young, H. A., Jahrling, P. B., Davis, K. J., Kagan, E. & Hensley, L. E. (2003b). Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 188, 16181629.[CrossRef][Medline]
Geisbert, T. W., Young, H. A., Jahrling, P. B., Davis, K. J., Larsen, T., Kagan, E. & Hensley, L. E. (2003c). Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163, 23712382.
Gibb, T. R., Norwood, D. A., Jr, Woollen, N. & Henchal, E. A. (2002). Viral replication and host gene expression in alveolar macrophages infected with Ebola virus (Zaire strain). Clin Diagn Lab Immunol 9, 1927.[CrossRef][Medline]
Gupta, M., Mahanty, S., Ahmed, R. & Rollin, P. E. (2001). Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1
and TNF-
and inhibit poly-IC-induced IFN-
in vitro. Virology 284, 2025.[CrossRef][Medline]
Harcourt, B. H., Sanchez, A. & Offermann, M. K. (1999). Ebola virus selectively inhibits responses to interferons, but not to interleukin-1
, in endothelial cells. J Virol 73, 34913496.
Ito, H., Watanabe, S., Sanchez, A., Whitt, M. A. & Kawaoka, Y. (1999). Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol 73, 89078912.
Jasenosky, L. D., Neumann, G., Lukashevich, I. & Kawaoka, Y. (2001). Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 75, 52055214.
Jeffers, S. A., Sanders, D. A. & Sanchez, A. (2002). Covalent modifications of the ebola virus glycoprotein. J Virol 76, 1246312472.
Khromykh, A. A. & Westaway, E. G. (1997). Subgenomic replicons of the flavivirus Kunjin: construction and applications. J Virol 71, 14971505.[Abstract]
Mahanty, S. & Bray, M. (2004). Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4, 487498.[CrossRef][Medline]
Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A. S., Nichol, S. T., Peters, C. J., Parren, P. W. & Burton, D. R. (1999). Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73, 60246030.
Peters, C. J., Sanchez, A., Rollin, P. E., Ksiazek, T. & Murphy, F. A. (1996). Filoviridae: Marburg and Ebola viruses. In Fields Virology, 3rd edn, pp. 11611176. Edited by P. M. Howley. Philadelphia: Lippincott-Raven Publishers.
Pourrut, X., Kumulungui, B., Wittmann, T., Moussavou, G., Delicat, A., Yaba, P., Nkoghe, D., Gonzalez, J. P. & Leroy, E. M. (2005). The natural history of Ebola virus in Africa. Microbes Infect 7, 10051014.[CrossRef][Medline]
Ray, R. B., Basu, A., Steele, R., Beyene, A., McHowat, J., Meyer, K., Ghosh, A. K. & Ray, R. (2004). Ebola virus glycoprotein-mediated anoikis of primary human cardiac microvascular endothelial cells. Virology 321, 181188.[CrossRef][Medline]
Ruthel, G., Demmin, G. L., Kallstrom, G. & 9 other authors (2005). Association of Ebola virus matrix protein VP40 with microtubules. J Virol 79, 47094719.
Ryabchikova, E., Kolesnikova, L. & Netesov, S. V. (1999a). Animal pathology of filoviral infections. Curr Top Microbiol Immunol 235, 145173.[Medline]
Sanchez, A., Trappier, S. G., Mahy, B. W., Peters, C. J. & Nichol, S. T. (1996). The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 93, 36023607.
Sanchez, A., Yang, Z. Y., Xu, L., Nabel, G. J., Crews, T. & Peters, C. J. (1998). Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 72, 64426447.
Simmons, G., Wool-Lewis, R. J., Baribaud, F., Netter, R. C. & Bates, P. (2002). Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 76, 25182528.
Stroher, U., West, E., Bugany, H., Klenk, H. D., Schnittler, H. J. & Feldmann, H. (2001). Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 75, 1102511033.
Sullivan, N. J., Peterson, M., Yang, Z. Y., Kong, W. P., Duckers, H., Nabel, E. & Nabel, G. J. (2005). Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol 79, 547553.
Takada, A., Watanabe, S., Ito, H., Okazaki, K., Kida, H. & Kawaoka, Y. (2000). Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278, 2026.[CrossRef][Medline]
Timmins, J., Scianimanico, S., Schoehn, G. & Weissenhorn, W. (2001). Vesicular release of ebola virus matrix protein VP40. Virology 283, 16.[CrossRef][Medline]
Varnavski, A. N., Young, P. R. & Khromykh, A. A. (2000). Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors. J Virol 74, 43944403.
Volchkov, V. E., Becker, S., Volchkova, V. A., Ternovoj, V. A., Kotov, A. N., Netesov, S. V. & Klenk, H. D. (1995). GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214, 421430.[CrossRef][Medline]
Volchkov, V. E., Feldmann, H., Volchkova, V. A. & Klenk, H. D. (1998). Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 95, 57625767.
Volchkov, V. E., Volchkova, V. A., Muhlberger, E., Kolesnikova, L. V., Weik, M., Dolnik, O. & Klenk, H. D. (2001). Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291, 19651969.
Volchkova, V. A., Feldmann, H., Klenk, H. D. & Volchkov, V. E. (1998). The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 250, 408414.[CrossRef][Medline]
Will, C., Muhlberger, E., Linder, D., Slenczka, W., Klenk, H. D. & Feldmann, H. (1993). Marburg virus gene 4 encodes the virion membrane protein, a type I transmembrane glycoprotein. J Virol 67, 12031210.
Yang, Z., Delgado, R., Xu, L., Todd, R. F., Nabel, E. G., Sanchez, A. & Nabel, G. J. (1998). Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 279, 10341037.
Yang, Z. Y., Duckers, H. J., Sullivan, N. J., Sanchez, A., Nabel, E. G. & Nabel, G. J. (2000). Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6, 886889.[CrossRef][Medline]
Yee, J. K., Miyanohara, A., LaPorte, P., Bouic, K., Burns, J. C. & Friedmann, T. (1994). A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci U S A 91, 95649568.
Zaki, S. R. & Goldsmith, C. S. (1999). Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 235, 97116.[Medline]
Received 19 July 2005;
accepted 14 January 2006.
This article has been cited by other articles:
![]() |
O. Reynard, M. Borowiak, V. A. Volchkova, S. Delpeut, M. Mateo, and V. E. Volchkov Ebolavirus Glycoprotein GP Masks both Its Own Epitopes and the Presence of Cellular Surface Proteins J. Virol., September 15, 2009; 83(18): 9596 - 9601. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Zampieri, J.-F. Fortin, G. P. Nolan, and G. J. Nabel The ERK Mitogen-Activated Protein Kinase Pathway Contributes to Ebola Virus Glycoprotein-Induced Cytotoxicity J. Virol., February 1, 2007; 81(3): 1230 - 1240. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |